Leap Investments’s Editas Medicine EDIT Stock Holding History

Leap Investments’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-18,500	Closed	-$548K	–	415
2019 Q4	$548K	Buy	+18,500	New	+$462K	0.26%	128

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Leap Investments's EDIT Position: Q1 2020 in Review

Leap Investments sold out of Editas Medicine (EDIT) in Q1 2020, closing a stake of 18,500 shares — an estimated $548K sold.

Leap Investments first reported a position in EDIT in Q4 2019 and held it in 1 quarter. The position peaked at $548K in Q4 2019. 199 funds tracked by Wall St. Rank hold EDIT as of Q1 2020.

Leap Investments reported no remaining Editas Medicine position as of Q1 2020 after selling out during the quarter.
Leap Investments sold 18,500 Editas Medicine shares in Q1 2020, an estimated $548K.
Leap Investments first reported a position in Editas Medicine in Q4 2019 and held it in 1 quarter.
Leap Investments's Editas Medicine position peaked at $548K in Q4 2019.
199 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.